Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2025-05-28

FDA Approved: BYETTA — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA entry documents a supplemental application for BYETTA (exenatide) submitted by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BYETTA (Exenatide)

Snippet

SUPPL AP for BYETTA (EXENATIDE)